Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Kairos Pharma, Ltd. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
KAPA
NYSE American
2834
kairospharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Kairos Pharma, Ltd.
Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial
- Feb 11th, 2025 1:30 pm
Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma
- Feb 6th, 2025 1:30 pm
Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024
- Jan 28th, 2025 1:15 pm
Kairos Pharma Provides Business Update and Outlook into 2025
- Jan 21st, 2025 1:30 pm
Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit
- Jan 7th, 2025 1:15 pm
Kairos Pharma to Participate in The Microcap Conference in January 2025
- Dec 16th, 2024 5:15 pm
Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial
- Dec 3rd, 2024 1:30 pm
Kairos Pharma Approved to Dual List on Upstream
- Nov 19th, 2024 1:30 pm
Kairos Pharma to Present at the LD Micro Main Event XVII
- Oct 22nd, 2024 1:00 pm
Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
- Oct 9th, 2024 8:30 pm
Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients
- Sep 24th, 2024 8:20 pm
Kairos Pharma Closing of $6.2 Million Initial Public Offering
- Sep 17th, 2024 8:29 pm
Kairos Pharma Prices $6.2 Million Initial Public Offering
- Sep 16th, 2024 2:49 pm
Scroll